Case Presentation:
A female in her forties presented to her primary care physician with a chief complaint of headaches. She reported that for the past several months she has had progressive fatigue, headaches, and epistaxis. She denied any fevers, chills, weight loss, or night sweats. Her past medical history was significant for a recently diagnosed anemia for which she was on oral iron therapy. At the time, her vital signs were normal. Physical exam was pertinent for pallor otherwise negative. Laboratory analysis was pertinent for a WBC of 3.6, Hg 7.4, HCT of 23.4, platelets of 109. Peripheral smear showed rouleaux formation. She had an elevated protein gap of 9.8. An SPEP was subsequently ordered. The patient was referred to hematology and oncology with suspicion of a paraproteinemia related to an underlying hematologic malignancy. Prior to her first visit with an oncologist, she presented to the ED with left sided central vision loss. Fundoscopic exam was pertinent for retinal venous engorgement and flame hemorrhages. An MRI and MRV were negative for any pathologic process. The SPEP that was ordered as an outpatient revealed a large monoclonal M spike at 8.5 g/dl. The presumed diagnosis at that time was central retinal vein occlusion as a consequence of hyperviscosity syndrome related to undiagnosed Waldenstrom’s Macroglobulinemia. Bone marrow biopsy showed a lymphoplasmacytic lymphoma consistent with the diagnosis. She was treated with plasmapheresis and concurrent intravenous Cyclophosphamide with near complete resolution of her vision as well as an improvement in her hematologic abnormalities.
Discussion:
Hyperviscosity syndrome (HVS) is a clinical feature in 10% to 30% of patients with Waldenstrom’s Macroglobulinemia (WM), occasional as a presenting manifestation. It can also be associated with other conditions including multiple myeloma, rheumatoid disease, polycythemia, sickle cell disease, leukemia, and spherocytosis. In WM, serum or plasma viscosity measurements reflect the amount and properties of the IgM paraprotein. IgM is a star‐shaped pentamer with a molecular size of 925 kDa. The most common manifestation of HVS is bleeding, usually skin or mucosal. Other common manifestations include blurred vision, headache, nystagmus, deafness, and ataxia. HVS can be diagnosed on physical exam by the fundoscopic finding of retinal venous engorgement resembling hot dogs on a string (“sausaging”). On peripheral smear, RBC’s can exhibit a stacking appearance or rouleaux formation. Cryoglobulinemia can also be seen which are mixed monoclonal IgM‐polyclonal IgG immune complexes. Treatment for HVS includes plasmapheresis which has been shown to reverse retinopathy and other clinical manifestations of patients with HVS. In the setting of WM induced HVS, chemotherapy is often begun concomitantly with plasmapheresis.
Conclusions:
Most patients with HVS have WM. Central vision loss can be a rare presentation of a patient with HVS. Our patient was successfully treated with Cyclophosphamide and plasmapheresis. She had complete resolution of her visual symptoms. In a patient with suspicion of HVS, a fundoscopic exam should be performed. If retinal venous engorgement is present, plasmapheresis should be considered. There are no randomized controlled trials of patients with HVS. Plasmapheresis has consistently shown to be effective and is currently the mainstay of treatment.